DE60221674D1 - Lyophilisierte formulierung enthaltend olanzapin - Google Patents
Lyophilisierte formulierung enthaltend olanzapinInfo
- Publication number
- DE60221674D1 DE60221674D1 DE60221674T DE60221674T DE60221674D1 DE 60221674 D1 DE60221674 D1 DE 60221674D1 DE 60221674 T DE60221674 T DE 60221674T DE 60221674 T DE60221674 T DE 60221674T DE 60221674 D1 DE60221674 D1 DE 60221674D1
- Authority
- DE
- Germany
- Prior art keywords
- formulation containing
- lyophilized formulation
- containing olanzapine
- olanzapine
- lyophilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012931 lyophilized formulation Substances 0.000 title 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title 1
- 229960005017 olanzapine Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30682901P | 2001-07-20 | 2001-07-20 | |
| US306829P | 2001-07-20 | ||
| US38647402P | 2002-06-07 | 2002-06-07 | |
| US386474P | 2002-06-07 | ||
| PCT/US2002/019799 WO2003007912A2 (en) | 2001-07-20 | 2002-07-05 | Lyophilized formulation comprising olanzapine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60221674D1 true DE60221674D1 (de) | 2007-09-20 |
| DE60221674T2 DE60221674T2 (de) | 2008-04-30 |
Family
ID=26975390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60221674T Expired - Lifetime DE60221674T2 (de) | 2001-07-20 | 2002-07-05 | Lyophilisierte formulierung enthaltend olanzapin |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20040176357A1 (de) |
| EP (1) | EP1423124B1 (de) |
| JP (1) | JP2004537546A (de) |
| KR (1) | KR20040017330A (de) |
| CN (1) | CN1537007A (de) |
| AR (1) | AR036180A1 (de) |
| AT (1) | ATE369137T1 (de) |
| AU (1) | AU2002320134B2 (de) |
| BR (1) | BR0211250A (de) |
| CA (1) | CA2448724A1 (de) |
| CO (1) | CO5540279A2 (de) |
| CY (1) | CY1107759T1 (de) |
| CZ (1) | CZ200484A3 (de) |
| DE (1) | DE60221674T2 (de) |
| DK (1) | DK1423124T3 (de) |
| EA (1) | EA006506B1 (de) |
| ES (1) | ES2289126T3 (de) |
| HR (1) | HRP20040037A2 (de) |
| HU (1) | HUP0401157A3 (de) |
| IL (1) | IL159098A0 (de) |
| MX (1) | MXPA04000541A (de) |
| MY (1) | MY135452A (de) |
| NZ (1) | NZ529667A (de) |
| PE (1) | PE20030281A1 (de) |
| PL (1) | PL366614A1 (de) |
| PT (1) | PT1423124E (de) |
| SI (1) | SI1423124T1 (de) |
| SK (1) | SK182004A3 (de) |
| SV (1) | SV2003001179A (de) |
| UA (1) | UA80095C2 (de) |
| WO (1) | WO2003007912A2 (de) |
| ZA (1) | ZA200400798B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004058773A1 (en) * | 2002-12-24 | 2004-07-15 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms |
| HU226410B1 (en) * | 2003-04-22 | 2008-11-28 | Egis Gyogyszergyar Nyilvanosan | Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them |
| GB0314149D0 (en) * | 2003-06-18 | 2003-07-23 | Generics Uk Ltd | Novel amorphous forms |
| EP1709053B1 (de) | 2004-01-27 | 2011-04-06 | Synthon B.V. | Stabile salze von olanzapin |
| WO2006076124A2 (en) * | 2004-12-16 | 2006-07-20 | Nektar Therapeutics | Stable, non-crystalline formulation comprising olanzapine |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| WO2007134845A2 (en) * | 2006-05-18 | 2007-11-29 | Synthon B.V. | Olanzapine pharmaceutical composition |
| CA3087698A1 (en) | 2018-01-05 | 2019-07-11 | Impel Neuropharma, Inc. | Intranasal delivery of olanzapine by precision olfactory device |
| HUP2100259A1 (hu) | 2021-07-07 | 2023-01-28 | Richter Gedeon Nyrt | Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények |
| CN115006406A (zh) * | 2021-12-28 | 2022-09-06 | 南京清普生物科技有限公司 | 一种稳定的奥氮平制剂 |
| WO2025056094A1 (zh) * | 2023-09-15 | 2025-03-20 | 广州帝奇医药技术有限公司 | 一种冻干制剂和注射液及其制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254545A (en) * | 1989-09-30 | 1993-10-19 | Eisai Co., Ltd. | Injectable preparations containing cephalosporin medicament |
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
-
2002
- 2002-05-07 UA UA2004010428A patent/UA80095C2/uk unknown
- 2002-07-05 EP EP02749634A patent/EP1423124B1/de not_active Expired - Lifetime
- 2002-07-05 SI SI200230629T patent/SI1423124T1/sl unknown
- 2002-07-05 PL PL02366614A patent/PL366614A1/xx not_active Application Discontinuation
- 2002-07-05 BR BR0211250-7A patent/BR0211250A/pt not_active IP Right Cessation
- 2002-07-05 EA EA200400211A patent/EA006506B1/ru not_active IP Right Cessation
- 2002-07-05 ES ES02749634T patent/ES2289126T3/es not_active Expired - Lifetime
- 2002-07-05 MX MXPA04000541A patent/MXPA04000541A/es active IP Right Grant
- 2002-07-05 WO PCT/US2002/019799 patent/WO2003007912A2/en not_active Ceased
- 2002-07-05 AT AT02749634T patent/ATE369137T1/de active
- 2002-07-05 JP JP2003513521A patent/JP2004537546A/ja active Pending
- 2002-07-05 CA CA002448724A patent/CA2448724A1/en not_active Abandoned
- 2002-07-05 PT PT02749634T patent/PT1423124E/pt unknown
- 2002-07-05 SK SK18-2004A patent/SK182004A3/sk unknown
- 2002-07-05 IL IL15909802A patent/IL159098A0/xx unknown
- 2002-07-05 CN CNA028144473A patent/CN1537007A/zh active Pending
- 2002-07-05 DE DE60221674T patent/DE60221674T2/de not_active Expired - Lifetime
- 2002-07-05 NZ NZ529667A patent/NZ529667A/en not_active IP Right Cessation
- 2002-07-05 AU AU2002320134A patent/AU2002320134B2/en not_active Expired
- 2002-07-05 HR HR20040037A patent/HRP20040037A2/hr not_active Application Discontinuation
- 2002-07-05 HU HU0401157A patent/HUP0401157A3/hu unknown
- 2002-07-05 CZ CZ200484A patent/CZ200484A3/cs unknown
- 2002-07-05 KR KR10-2004-7000829A patent/KR20040017330A/ko not_active Ceased
- 2002-07-05 DK DK02749634T patent/DK1423124T3/da active
- 2002-07-05 US US10/480,617 patent/US20040176357A1/en not_active Abandoned
- 2002-07-17 PE PE2002000636A patent/PE20030281A1/es active IP Right Grant
- 2002-07-18 AR ARP020102700A patent/AR036180A1/es not_active Application Discontinuation
- 2002-07-18 MY MYPI20022723A patent/MY135452A/en unknown
- 2002-07-19 SV SV2002001179A patent/SV2003001179A/es not_active Application Discontinuation
-
2003
- 2003-12-31 CO CO03113784A patent/CO5540279A2/es not_active Application Discontinuation
-
2004
- 2004-01-30 ZA ZA2004/00798A patent/ZA200400798B/en unknown
-
2007
- 2007-10-11 CY CY20071101308T patent/CY1107759T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20033384L (no) | Farmasoytisk formulering | |
| FI20011478A0 (fi) | Farmaseuttinen koostumus | |
| ITTO20010008A0 (it) | Formulazione farmaceutica | |
| NO20033785L (no) | Farmasöytisk formulering | |
| BR0210619A (pt) | composição | |
| NO20035627D0 (no) | Farmasöytisk formulering | |
| FI20022128L (fi) | Farmaseuttinen koostumus | |
| DE60221674D1 (de) | Lyophilisierte formulierung enthaltend olanzapin | |
| ITTO20020747A0 (it) | Composizione | |
| ITTO20020745A0 (it) | Composizione | |
| EP1413314A4 (de) | Medizinische zusammensetzungen | |
| NO20040250L (no) | Metyl-tieno-benzodiazepinlyofilisert formulering | |
| NO20041236L (no) | Farmasoytisk formulering | |
| SE0100477D0 (sv) | Novel formulation | |
| SE0100478D0 (sv) | Novel formulation | |
| SE0100199D0 (sv) | New formulation | |
| SE0101171D0 (sv) | Pharmaceutical formulation | |
| SE0101325D0 (sv) | Pharmaceutical formulation | |
| SE0102957D0 (sv) | Pharmaceutical formulation | |
| SE0103565D0 (sv) | Pharmaceutical formulation | |
| SE0102069D0 (sv) | Pharmaceutical formulation | |
| SE0102572D0 (sv) | Pharmaceutical formulation | |
| SE0101326D0 (sv) | Pharmaceutical formulation | |
| DK1307264T3 (da) | Hidtil ukendt farmaceutisk præparat | |
| FI5468U1 (fi) | Farmaseuttinen koostumus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |